利奈唑胺治疗恶性肿瘤患者中性粒细胞减少并发革兰阳性菌感染的疗效观察

Efficacy of linezolid in treatment of neutropenia complicated by gram-positive bacteria infections in malignant tumor patients

目的评价利奈唑胺治疗中性粒细胞减少患者并发革兰阳性菌感染的临床疗效与安全性。方法选择62例中性粒细胞减少并发革兰阳性菌感染的恶性肿瘤患者,给予所有患者静脉滴注利奈唑胺600mg、1次/12h,根据治疗情况连续使用7～21d;观察治疗疗效以及患者的不良反应。结果在使用利奈唑胺治疗后,患者临床治愈43例,有效12例,进步2例,无效5例,总有效率为88.71%,药物不良反应总发生率为11.29%。结论利奈唑胺治疗恶性肿瘤患者中性粒细胞减少并发革兰阳性菌感染临床疗效确切,不良反应少。

OBJECTIVE To evaluate the clinical efficacy and safety of linezolid in the treatment of neutropenia complicated by gram-positive bacteria infections in malignant tumor patients. METHODS A total of 62 neutropenic malignant tumor patients with gram-positive bacteria infections were chosen, all the patients were given the intravenous infusion of linezolid 600 mg for 12h once, this regimen continued for 7 -- 21 d according to the treatment~ the treatment efficacy and the adverse reactions were observed. RESULTS After the treatment with linezolid, 43 patients were cured, 12 patients were effective, 2 cases improved, and 5 patients were ineffective, the total effective rate was 88. 71%, the total incidence of drug adverse reactions was 11. 29%. CONCLUSION Linezolid has significant clinical efficacy and less adverse reactions in treatment of neutropenia complicated by gram：positive bacteria infections in the malignant tumor patients.